These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28709828)

  • 1. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
    Wenthur CJ; Cai X; Ellis BA; Janda KD
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design.
    Cai X; Whitfield T; Hixon MS; Grant Y; Koob GF; Janda KD
    J Med Chem; 2013 May; 56(9):3701-9. PubMed ID: 23627877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the effects of hapten stability on cocaine vaccine immunogenicity.
    Cai X; Whitfield T; Moreno AY; Grant Y; Hixon MS; Koob GF; Janda KD
    Mol Pharm; 2013 Nov; 10(11):4176-84. PubMed ID: 23927436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cocaine catalytic antibodies: the primary importance of linker effects.
    Matsushita M; Hoffman TZ; Ashley JA; Zhou B; Wirsching P; Janda KD
    Bioorg Med Chem Lett; 2001 Jan; 11(2):87-90. PubMed ID: 11206477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hapten optimization for cocaine vaccine with improved cocaine recognition.
    Ramakrishnan M; Kinsey BM; Singh RA; Kosten TR; Orson FM
    Chem Biol Drug Des; 2014 Sep; 84(3):354-63. PubMed ID: 24803171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hapten design for the generation of catalytic antibodies.
    Thomas NR
    Appl Biochem Biotechnol; 1994; 47(2-3):345-72. PubMed ID: 7944348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flagellin as carrier and adjuvant in cocaine vaccine development.
    Lockner JW; Eubanks LM; Choi JL; Lively JM; Schlosburg JE; Collins KC; Globisch D; Rosenfeld-Gunn RJ; Wilson IA; Janda KD
    Mol Pharm; 2015 Feb; 12(2):653-62. PubMed ID: 25531528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
    Odenbaugh AL; Helms ED; Iverson BL
    Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catalytic antibodies: hapten design strategies and screening methods.
    Xu Y; Yamamoto N; Janda KD
    Bioorg Med Chem; 2004 Oct; 12(20):5247-68. PubMed ID: 15388154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition, antigen design, and catalytic antibody production.
    Tramontano A
    Appl Biochem Biotechnol; 1994; 47(2-3):257-73; discussion 273-5. PubMed ID: 7944342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis.
    Spivak DA; Hoffman TZ; Moore AH; Taylor MJ; Janda KD
    Bioorg Med Chem; 1999 Jun; 7(6):1145-50. PubMed ID: 10428386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of single chain anti-cocaine catalytic antibodies.
    McKenzie KM; Mee JM; Rogers CJ; Hixon MS; Kaufmann GF; Janda KD
    J Mol Biol; 2007 Jan; 365(3):722-31. PubMed ID: 17084858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The scope of antibody catalysis.
    Jacobsen JR; Schultz PG
    Curr Opin Struct Biol; 1995 Dec; 5(6):818-24. PubMed ID: 8749371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.
    Taylor JJ; Laudenbach M; Tucker AM; Jenkins MK; Pravetoni M
    J Immunol Methods; 2014 Mar; 405():74-86. PubMed ID: 24462800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate-assisted antibody catalysis.
    Deng S; Bharat N; de Prada P; Landry DW
    Org Biomol Chem; 2004 Feb; 2(3):288-90. PubMed ID: 14747854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positional linker effects in haptens for cocaine immunopharmacotherapy.
    Ino A; Dickerson TJ; Janda KD
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4280-3. PubMed ID: 17531484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural convergence in the active sites of a family of catalytic antibodies.
    Charbonnier JB; Golinelli-Pimpaneau B; Gigant B; Tawfik DS; Chap R; Schindler DG; Kim SH; Green BS; Eshhar Z; Knossow M
    Science; 1997 Feb; 275(5303):1140-2. PubMed ID: 9027317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarities of hydrolytic antibodies revealed by their X-ray structures: a review.
    Charbonnier JB; Gigant B; Golinelli-Pimpaneau B; Knossow M
    Biochimie; 1997 Nov; 79(11):653-60. PubMed ID: 9479447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.